Commercialization Programs & Accelerators
Overview
MSK takes pride in our exceptional record of building productive relationships with entrepreneurs, investors, life sciences, and digital health companies, as well as academic-research collaborators throughout the global healthcare sector.
We seek to encourage, develop, and enhance these external partnerships through an outstanding network of business accelerators and commercialization-focused programs—all aimed at harnessing advanced technologies and new discoveries to improve the diagnosis, early detection, treatment, and care of cancer patients around the world.
Leading digital health companies that participate in the MSK Innovation Hub
MSK Innovation Hub
MSK Innovation Hub is an accelerator program focused on jump-starting innovation by encouraging collaborations between MSK and cutting-edge digital health companies.
Learn more about our ongoing partnerships and application process
MSK iHub Challenge
The iHub Challenge program brings together cohorts of digital healthcare companies for three-month sessions focused on strategic healthcare themes identified by MSK as areas of need and opportunity within the global healthcare sector.
Dr. Paul Sabbatini leads an MSK iHub Challenge working session
The goal of the MSK Therapeutics Accelerator is to develop and advance therapeutics for people with cancer.
MSK Therapeutics Accelerator
With a focus on accelerating therapeutics innovation, this program provides select projects from biotech and pharmaceutical companies with access to MSK expert teams, infrastructure, and related resources across all stages of drug development through regulatory approval.
MSK Technology Development Fund (TDF)
MSK’s Technology Development Fund (TDF) is an investment vehicle that provides critical gap funding to MSK life sciences and digital health initiatives with strong commercialization potential. Its record of success includes two FDA approved drugs, more than 30 industry partnerships and successful startups, and an extensive portfolio of research breakthroughs with commercial potential.
Dr. Anaeze (Anii) Offodile and Dr. Christopher Klebanoff join other attendees at an event commemorating MSK’s TDF